Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H21Cl2NO |
| Molecular Weight | 314.25 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC(Cl)=C(Cl)C=C3)N2C
InChI
InChIKey=PGYDXVBZYKQYCS-VPWBDBDCSA-N
InChI=1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1
| Molecular Formula | C16H21Cl2NO |
| Molecular Weight | 314.25 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
NS-2359, an orally active, triple monoamine reuptake inhibitor that inhibits the reuptake of dopamine, noradrenaline and serotonin, is being developed by Saniona and the Treatment Research Center (TRC) at the University of Pennsylvania for the treatment of Cocaine abuse. NS-2359’s pharmacological profile means that it may be able to reduce cocaine withdrawal symptoms, reduce cocaine craving and reduce cocaine-induced euphoria. Previously NS-2359 was in clinical trials for the treatment of attention-deficit hyperactivity disorder and major depressive disorder, but development was discontinued due to lack of effectiveness.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18554401 | https://adisinsight.springer.com/drugs/800010231
Curator's Comment: The slow entrance of NS-2359 into the human brain makes it a candidate for the treatment of ADHD with minimal potential for abuse.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. | 2008 Jun 13 |
|
| Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. | 2012 May |
Sample Use Guides
Cocaine Use Disorder: the initial dose of the NS-2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:10:39 GMT 2023
by
admin
on
Sat Dec 16 07:10:39 GMT 2023
|
| Record UNII |
76H76554PA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NS-2359
Created by
admin on Sat Dec 16 07:10:39 GMT 2023 , Edited by admin on Sat Dec 16 07:10:39 GMT 2023
|
PRIMARY | |||
|
76H76554PA
Created by
admin on Sat Dec 16 07:10:39 GMT 2023 , Edited by admin on Sat Dec 16 07:10:39 GMT 2023
|
PRIMARY | |||
|
843660-54-8
Created by
admin on Sat Dec 16 07:10:39 GMT 2023 , Edited by admin on Sat Dec 16 07:10:39 GMT 2023
|
SUPERSEDED | |||
|
195875-68-4
Created by
admin on Sat Dec 16 07:10:39 GMT 2023 , Edited by admin on Sat Dec 16 07:10:39 GMT 2023
|
PRIMARY | |||
|
68470595
Created by
admin on Sat Dec 16 07:10:39 GMT 2023 , Edited by admin on Sat Dec 16 07:10:39 GMT 2023
|
PRIMARY | |||
|
DB05805
Created by
admin on Sat Dec 16 07:10:39 GMT 2023 , Edited by admin on Sat Dec 16 07:10:39 GMT 2023
|
PRIMARY | |||
|
DTXSID401004649
Created by
admin on Sat Dec 16 07:10:39 GMT 2023 , Edited by admin on Sat Dec 16 07:10:39 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
